110.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BNTX Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$107.34
Aprire:
$112.4
Volume 24 ore:
906.00K
Relative Volume:
1.02
Capitalizzazione di mercato:
$26.45B
Reddito:
$2.97B
Utile/perdita netta:
$-812.83M
Rapporto P/E:
-32.40
EPS:
-3.3962
Flusso di cassa netto:
$-1.24B
1 W Prestazione:
-2.45%
1M Prestazione:
+0.03%
6M Prestazione:
-6.07%
1 anno Prestazione:
+34.17%
Biontech Se Adr Stock (BNTX) Company Profile
Confronta BNTX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BNTX
Biontech Se Adr
|
110.03 | 25.80B | 2.97B | -812.83M | -1.24B | -3.3962 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 118.67B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
571.54 | 59.23B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
419.56 | 52.67B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
690.32 | 41.24B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
304.30 | 32.36B | 3.81B | -644.79M | -669.77M | -6.24 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-05 | Reiterato | H.C. Wainwright | Buy |
2025-05-29 | Iniziato | Goldman | Neutral |
2025-03-13 | Iniziato | Citigroup | Buy |
2025-01-10 | Iniziato | Truist | Buy |
2024-12-11 | Iniziato | Wells Fargo | Overweight |
2024-12-02 | Reiterato | BMO Capital Markets | Outperform |
2024-11-19 | Iniziato | Berenberg | Buy |
2024-11-19 | Aggiornamento | Evercore ISI | In-line → Outperform |
2024-11-08 | Aggiornamento | Goldman | Neutral → Buy |
2024-09-24 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2024-09-17 | Aggiornamento | Jefferies | Hold → Buy |
2024-09-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
2024-08-07 | Aggiornamento | Deutsche Bank | Hold → Buy |
2024-08-02 | Aggiornamento | HSBC Securities | Hold → Buy |
2024-05-14 | Iniziato | Evercore ISI | In-line |
2024-02-23 | Iniziato | BMO Capital Markets | Outperform |
2024-01-05 | Iniziato | Oppenheimer | Perform |
2023-12-01 | Downgrade | JP Morgan | Neutral → Underweight |
2023-10-16 | Downgrade | HSBC Securities | Buy → Hold |
2023-07-14 | Iniziato | HSBC Securities | Buy |
2023-05-17 | Aggiornamento | Redburn | Neutral → Buy |
2022-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
2022-08-17 | Iniziato | Cowen | Market Perform |
2022-07-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2022-07-06 | Ripresa | Canaccord Genuity | Buy |
2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
2021-12-16 | Iniziato | Morgan Stanley | Equal-Weight |
2021-11-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2021-10-22 | Iniziato | Deutsche Bank | Hold |
2021-10-07 | Iniziato | Jefferies | Hold |
2021-08-11 | Aggiornamento | Bryan Garnier | Neutral → Buy |
2021-07-19 | Ripresa | Wolfe Research | Outperform |
2021-06-16 | Downgrade | Redburn | Neutral → Sell |
2021-05-18 | Iniziato | Goldman | Neutral |
2021-05-11 | Downgrade | Bryan Garnier | Buy → Neutral |
2020-12-01 | Downgrade | BofA Securities | Buy → Neutral |
2020-08-03 | Ripresa | Berenberg | Buy |
2020-07-21 | Aggiornamento | BofA Securities | Neutral → Buy |
2020-06-30 | Downgrade | H.C. Wainwright | Buy → Neutral |
2020-05-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2020-04-28 | Downgrade | BofA/Merrill | Buy → Neutral |
2020-03-18 | Downgrade | JP Morgan | Overweight → Neutral |
2020-03-09 | Iniziato | H.C. Wainwright | Neutral |
2020-01-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2020-01-22 | Downgrade | UBS | Buy → Neutral |
2019-11-05 | Iniziato | Wolfe Research | Outperform |
2019-11-04 | Iniziato | Berenberg | Buy |
2019-11-04 | Iniziato | BofA/Merrill | Buy |
2019-11-04 | Iniziato | Canaccord Genuity | Buy |
2019-11-04 | Iniziato | JP Morgan | Overweight |
2019-11-04 | Iniziato | SVB Leerink | Outperform |
2019-11-04 | Iniziato | UBS | Buy |
Mostra tutto
Biontech Se Adr Borsa (BNTX) Ultime notizie
BioNTech ADR Earns Relative Strength Rating Upgrade - MSN
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth - Benzinga
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update04.08.25News - Ariva
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
BioNTech (BNTX) Expected to Announce Quarterly Earnings on Monday - Defense World
BioNTech’s BNT327: A Promising New Approach in Breast Cancer Treatment - TipRanks
BioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should Know - Yahoo Finance
Cancer Vaccine Market Research Service Featuring the Top 5 Developers and Pipeline Activities - GlobeNewswire Inc.
Best Momentum Stocks to Buy for July 29th - Yahoo Finance
New Strong Buy Stocks for July 29th - Yahoo Finance
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares Acquired by Kestra Private Wealth Services LLC - Defense World
Cerity Partners LLC Invests $357,000 in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union - Ariva
BioNTech’s Promising Study on Pancreatic Cancer Treatment: Market Implications - TipRanks
Has BioNTech (BNTX) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Genmab and BioNTech Launch Promising Study for Advanced Colorectal Cancer Treatment - TipRanks
BioNTech’s New Study on PDAC Treatment: Key Insights for Investors - TipRanks
BioNTech’s BNT327 Clinical Trial: A New Hope for Small-Cell Lung Cancer? - MSN
Pfizer and BioNTech’s New Shingles Vaccine Study: What Investors Need to Know - TipRanks
BioNTech’s BNT327 Trial: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks
BioNTech’s Promising Lung Cancer Trial: A Potential Game-Changer for NSCLC Treatment - TipRanks
BioNTech Announces Ryan Richardson to Step Down from the Management Board17.07.25News - Ariva
BioNTech’s DYNASTY-Breast02 Study: A New Hope for Metastatic Breast Cancer? - TipRanks
OneDigital Investment Advisors LLC Makes New Investment in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
BioNTech’s Promising Phase III Trial for Recurrent Endometrial Cancer - TipRanks
BioNTech’s Latest Clinical Trial: A New Hope for Lung Cancer Treatment? - TipRanks
BioNTech’s Phase II Trial: A Potential Game-Changer in Colorectal Cancer Treatment - TipRanks
Regeneron and BioNTech’s Promising Lung Cancer Trial: What Investors Need to Know - TipRanks
BioNTech SE Receives Buy Rating from BMO Capital with $143 Price Target - AInvest
Genmab and BioNTech’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks
Genmab and BioNTech’s Immunoradiotherapy Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Genmab and BioNTech’s Promising Cancer Trial: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A New Hope for Cancer Treatment? - TipRanks
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
GAMMA Investing LLC Sells 334 Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
BioNTech’s Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks
Genmab and BioNTech’s Promising Immunoradiotherapy Study for Metastatic Tumors - TipRanks
Genmab and BioNTech’s Pioneering Cancer Trial: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1056 Study: A Potential Game-Changer in Oncology - TipRanks
Genmab and BioNTech’s GEN1042 Study: A New Hope in Cancer Treatment - TipRanks
Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
BioNTech SE’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks
BioNTech’s Cancer Therapy Study Withdrawn: Implications for Investors - TipRanks
BioNTech’s BNT327: A Promising Step in Breast Cancer Treatment - TipRanks
BioNTech’s Latest Clinical Trial: A New Hope for NSCLC Treatment? - TipRanks
What is HC Wainwright’s Forecast for BioNTech Q3 Earnings? - Defense World
BioNTech ADR Gets Relative Strength Rating Upgrade - Investor's Business Daily
BioNTech’s Promising Phase II Study: A Potential Game-Changer in Cancer Treatment - TipRanks
BioNTech SE’s Promising Study on Pancreatic Cancer Treatment: What Investors Need to Know - TipRanks
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Yahoo Finance
Equities Analysts Issue Forecasts for BioNTech Q4 Earnings - Defense World
Biontech Se Adr Azioni (BNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):